צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: Invivyd (IVVD)

Invivyd, Inc. (IVVD) aims for dominance in the antiviral antibody segment by scaling biodefense solutions. On GURU.Markets, the current YoY revenue growth rate over the TTM reflects the market consensus, where the current level is 26.50. The implementation of robotic screening accelerates the release of innovations, yet high viral volatility and regulatory barriers create significant financial risks for the company.
Invivyd - פילוחים אנליטיים ומדדי מפתח (IVVD)

To filter for fundamentally strong assets, an investor must separate market noise from actual business expansion. This TTM year-over-year sales growth percentage on GURU.Markets measures the annual sales rate while excluding seasonality, which for Invivyd, Inc. (IVVD) confirms the commercial effectiveness of adapting antibodies to new strains and mitigates regulatory risks through objective revenue dynamics.